AAP
NMRA icon

Arax Advisory Partners’s Neumora Therapeutics NMRA Stock Holding History

Arax Advisory Partners’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$245 Buy
+144
New +$274 ﹤0.01% 5080
2025
Q4 		– Sell
-12,445
Closed -$22.6K – 4390
2025
Q3 		$22.6K Buy
+12,445
New +$20.1K ﹤0.01% 2209
2025
Q1 		– Sell
-91
Closed -$965 – 2920
2024
Q4 		$965 Hold
91
– – ﹤0.01% 2186
2024
Q3 		$1.2K Hold
91
– – ﹤0.01% 2202
2024
Q2 		$895 Buy
+91
New +$942 ﹤0.01% 2202

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arax Advisory Partners's NMRA Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Neumora Therapeutics (NMRA) in Q2 2026: 144 shares worth $245. The stake represents ﹤0.01% of the portfolio and ranks #5080 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in NMRA as recently as Q3 2025.

Arax Advisory Partners first reported a position in NMRA in Q2 2024 and has held it in 5 quarters since. The position peaked at $22.6K in Q3 2025. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • Arax Advisory Partners held 144 shares of Neumora Therapeutics worth $245 as of Q2 2026.
  • Neumora Therapeutics was a new Arax Advisory Partners position in Q2 2026.
  • Neumora Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #5080 holding.
  • Arax Advisory Partners first reported a position in Neumora Therapeutics in Q2 2024 and has held it in 5 quarters since.
  • Arax Advisory Partners's Neumora Therapeutics position peaked at $22.6K in Q3 2025.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.